Health and Healthcare
How Much New Eli Lilly Product Launches Boosted the Bottom Line
Published:
Eli Lilly and Co. (NYSE: LLY) reported its second-quarter earnings Thursday before the markets opened. The company had $0.90 in earnings per share (EPS) on $4.98 billion in revenue. That was against Thomson Reuters consensus estimates of $0.74 in EPS on $4.91 billion in revenue. In the same period of the previous year EPS were $0.68 and revenue $4.94 billion.
Guidance for the 2015 full year EPS was revised to $3.20 to $3.30, reflecting solid underlying performance in the first six months of the year. Revenue guidance was revised to $19.7 billion to $20.0 billion, up from $19.5 billion to $20.0 billion. The consensus estimates are $3.18 in EPS on $19.80 billion in revenue for the 2015 full year.
For the most recent quarter, gross margin as a percentage of revenue was 79.2%, an increase of 250 basis points from the second quarter of 2014. The increase in gross margin percentage was due to the impact of foreign exchange rates on international inventories sold.
In terms of its product sales, Eli Lilly reported (on a year-over-year basis):
- Humalog, $654.3 million, down 7%
- Alimta, $664.3 million, down 7%
- Cialis, $567.9 million
- Humlin, $316.4 million, down 10%
- Forteo, $328.4 million, up 6%
- Cymbalta, $274.1 million, down 32%
- Zyprexa, $253.7 million, up 4%
- Strattera, $191.8 million, down 3%
- Effient, $128.8 million, down 4%
- Trajenta, $80.0 million, down 11%
- Cyramza, $87.7 million
- Evista, $59.7 million, down 45%
- Animal Health, $840.8 million, up 40%
ALSO READ: 5 S&P 500 Companies That Are Buying Back the Most Stock
John C. Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly, said:
Lilly remains on track to return to growth in 2015, driven by strong underlying business performance, including uptake of our recently launched products — Jardiance, Trulicity and Cyramza. With tangible results from launches of new medicines and continued progress in our pipeline, along with careful control of operational expenses, we are confident that our innovation-based strategy will continue to provide the basis for solid growth in the years ahead.
Shares of Eli Lilly were flat at $86.41 Thursday morning. The stock has a consensus analyst price target of $89.71 and a 52-week trading range of $60.14 to $90.18.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
